^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PLCG2 D1140N

    i
    Other names: PLCG2, Phospholipase C Gamma 2, 1-Phosphatidylinositol 4,5-Bisphosphate Phosphodiesterase Gamma-2, Phospholipase C, Gamma 2 (Phosphatidylinositol-Specific), Phosphoinositide Phospholipase C-Gamma-2, Phospholipase C-IV, PLC-Gamma-2, PLC-IV, Phospholipase C-Gamma-2, APLAID, FCAS3
    Entrez ID:
    5336
    Related biomarkers:
    Mutation
    Associations

    News

    Trials
    9ms
    Bruton's Tyrosine Kinase and Phospholipase C-Gamma 2 Mutational Profiles in Pooled Analysis of Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib (IWCLL 2023)
    Novel, non-C481 BTK mutations have been described, including BTK L528W, which has been reported in patients treated with ibrutinib, zanubrutinib, and pirtobrutinib (Maddocks, JAMA Oncol. This is the largest dataset characterizing the incidence and patterns of BTK and PLCG2 mutations in patients with CLL treated with ibrutinib. BTK C481 mutations are the most frequently occurring mutations. PLCG2 mutations occur across the gene at a low incidence per locus (<5%).
    Retrospective data
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus) • PLCG2 (Phospholipase C Gamma 2)
    |
    TP53 mutation • BTK C481S • PLCG2 mutation • BTK mutation • BTK C481 • BTK C481R • BTK C481Y • BTK R665W • BTK T474I • BTK L845F • PLCG2 D1140N • PLCG2 L845F
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Jaypirca (pirtobrutinib)